Tornier N.V. (WMGI) SEC Filing 10-K Annual report for the fiscal year ending Sunday, January 2, 2011

Exhibit 99.1

FOR IMMEDIATE RELEASE

TORNIER REPORTS FINANCIAL RESULTS FOR 2010 AND PROVIDES 2011 OUTLOOK

Sales Growth of 13% in 2010 Drives Adjusted EBITDA Increase of 76%

Extremity Product Lines Record 15% 2010 Growth

AMSTERDAM, The Netherlands, March 1, 2011 — Tornier N.V. (NASDAQ: TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported full year sales of $227.4 million in 2010 compared to sales of $201.5 million in 2009, an increase of 13% as reported and 14% in constant currency over the prior year.  The extremities product categories, which represent approximately 77% of company sales, were $176.0 million in 2010 compared to extremity sales of $152.5 million in 2009, an increase of 15% as reported and 16% in constant currency over the prior year.  Tornier’s sales in the fourth quarter of 2010 were $61.3 million compared to sales of $57.3 million in the fourth quarter of 2009, an increase of 7% as reported and 10% in constant currency.  Fourth quarter 2010 sales of Tornier’s extremity product lines increased by 9% as reported and 11% in constant currency over fourth quarter 2009.

Douglas W. Kohrs, President and Chief Executive Officer of Tornier, commented, “We are pleased to have delivered another year of solid double digit sales growth in 2010 as Tornier’s new product momentum, global expansion, and strong position in the extremities market overcame a challenging economic environment for the healthcare industry and the orthopaedic market.  We recently highlighted six already launched new products at the American Academy of Orthopaedic Surgeons meeting and we plan a total of 19 product launches for the full year.  We are excited about the contribution that these new products will make to sustain balanced growth across our product lines and geographic markets.”

Tornier’s 2010 adjusted EBITDA, as defined in both our most recent Form S-1 and in the GAAP to non-GAAP reconciliation provided later in this release, was reported at $18.6 million or 8.2% of sales, an increase of 76% compared to $10.6 million, or 5.3% of sales, in 2009.  The Company reported adjusted EBITDA of $5.2 million, or 8.5% of sales, for the fourth quarter of 2010 compared to $5.0 million for the fourth quarter of 2009.

Mr. Kohrs continued, “We are encouraged by the significant increase in adjusted EBITDA in 2010 which we believe evidences the margin expansion opportunity in our business model.  As we look forward to 2011, our first year as a publicly traded company, we remain committed to continued improvement in profitability driven by above market top line growth.”